S&P 500   3,973.97 (+1.86%)
DOW   31,939.83 (+2.17%)
QQQ   293.45 (+1.65%)
AAPL   142.64 (+3.67%)
MSFT   261.35 (+3.48%)
FB   196.59 (+1.58%)
GOOGL   2,232.96 (+2.52%)
AMZN   2,124.52 (-1.27%)
TSLA   677.85 (+2.10%)
NVDA   168.56 (+0.97%)
BABA   87.36 (+0.66%)
NIO   15.88 (-3.41%)
AMD   93.97 (+0.50%)
CGC   5.29 (-4.17%)
MU   69.80 (+1.31%)
T   20.81 (+2.01%)
GE   76.13 (+1.17%)
F   12.92 (+3.36%)
DIS   104.27 (+1.81%)
AMC   11.75 (-2.33%)
PFE   53.15 (+1.30%)
PYPL   81.79 (+1.55%)
NFLX   185.79 (-0.30%)
S&P 500   3,973.97 (+1.86%)
DOW   31,939.83 (+2.17%)
QQQ   293.45 (+1.65%)
AAPL   142.64 (+3.67%)
MSFT   261.35 (+3.48%)
FB   196.59 (+1.58%)
GOOGL   2,232.96 (+2.52%)
AMZN   2,124.52 (-1.27%)
TSLA   677.85 (+2.10%)
NVDA   168.56 (+0.97%)
BABA   87.36 (+0.66%)
NIO   15.88 (-3.41%)
AMD   93.97 (+0.50%)
CGC   5.29 (-4.17%)
MU   69.80 (+1.31%)
T   20.81 (+2.01%)
GE   76.13 (+1.17%)
F   12.92 (+3.36%)
DIS   104.27 (+1.81%)
AMC   11.75 (-2.33%)
PFE   53.15 (+1.30%)
PYPL   81.79 (+1.55%)
NFLX   185.79 (-0.30%)
S&P 500   3,973.97 (+1.86%)
DOW   31,939.83 (+2.17%)
QQQ   293.45 (+1.65%)
AAPL   142.64 (+3.67%)
MSFT   261.35 (+3.48%)
FB   196.59 (+1.58%)
GOOGL   2,232.96 (+2.52%)
AMZN   2,124.52 (-1.27%)
TSLA   677.85 (+2.10%)
NVDA   168.56 (+0.97%)
BABA   87.36 (+0.66%)
NIO   15.88 (-3.41%)
AMD   93.97 (+0.50%)
CGC   5.29 (-4.17%)
MU   69.80 (+1.31%)
T   20.81 (+2.01%)
GE   76.13 (+1.17%)
F   12.92 (+3.36%)
DIS   104.27 (+1.81%)
AMC   11.75 (-2.33%)
PFE   53.15 (+1.30%)
PYPL   81.79 (+1.55%)
NFLX   185.79 (-0.30%)
S&P 500   3,973.97 (+1.86%)
DOW   31,939.83 (+2.17%)
QQQ   293.45 (+1.65%)
AAPL   142.64 (+3.67%)
MSFT   261.35 (+3.48%)
FB   196.59 (+1.58%)
GOOGL   2,232.96 (+2.52%)
AMZN   2,124.52 (-1.27%)
TSLA   677.85 (+2.10%)
NVDA   168.56 (+0.97%)
BABA   87.36 (+0.66%)
NIO   15.88 (-3.41%)
AMD   93.97 (+0.50%)
CGC   5.29 (-4.17%)
MU   69.80 (+1.31%)
T   20.81 (+2.01%)
GE   76.13 (+1.17%)
F   12.92 (+3.36%)
DIS   104.27 (+1.81%)
AMC   11.75 (-2.33%)
PFE   53.15 (+1.30%)
PYPL   81.79 (+1.55%)
NFLX   185.79 (-0.30%)
LON:SUMM

Summit Therapeutics (SUMM) Share Forecast, Price & News

GBX 20.50
0.00 (0.00%)
(As of 02/21/2020)
Add
Compare
Today's Range
18
20.50
50-Day Range
20.50
20.50
52-Week Range
18
32.50
Volume
280,318 shs
Average Volume
382,504 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive SUMM News and Ratings via Email

Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Summit Therapeutics logo

About Summit Therapeutics

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The company's lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Drugs - Generic
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Optionable
Not Optionable

Company Calendar

Last Earnings
6/12/2019
Today
5/23/2022

MarketRank

Overall MarketRank

0.77 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -













Summit Therapeutics (LON:SUMM) Frequently Asked Questions

How were Summit Therapeutics' earnings last quarter?

Summit Therapeutics PLC (LON:SUMM) issued its quarterly earnings results on Wednesday, June, 12th. The company reported ($3.00) earnings per share for the quarter, beating the consensus estimate of ($4.00) by $1.00.
View Summit Therapeutics' earnings history
.

Who are Summit Therapeutics' key executives?
Summit Therapeutics' management team includes the following people:
  • Mr. Glyn O. Edwards, CEO & Exec. Director (Age 63)
  • Mr. Erik Ostrowski, Chief Financial Officer (Age 46)
  • Prof. David Roblin, COO, Chief Medical Officer and Pres of R&D (Age 53)
  • Prof. Kay Davies, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor (Age 69)
  • Ms. Michelle Avery, Director of Investor Relations
What other stocks do shareholders of Summit Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Summit Therapeutics investors own include Summit Therapeutics (SMMT), American Airlines Group (AAL), Acadia Healthcare (ACHC), Avesoro Resources (ASO), Diana Shipping (DSX), 2570 (JLF.L) (JLF), National Fuel Gas (NFG), Tailored Brands (TLRD), The Weir Group (WEIR) and Acacia Mining (ABGLF).

What is Summit Therapeutics' stock symbol?

Summit Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SUMM."

How do I buy shares of Summit Therapeutics?

Shares of SUMM and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Summit Therapeutics' stock price today?

One share of SUMM stock can currently be purchased for approximately GBX 20.50.

What is Summit Therapeutics' official website?

The official website for Summit Therapeutics is www.summitplc.com.

How can I contact Summit Therapeutics?

Summit Therapeutics' mailing address is 136A Eastern Avenue, ABINGDON, OX14 4SB, United Kingdom. The company can be reached via phone at +44-1235-443939.

This page was last updated on 5/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.